Furthermore, with the introduction of various combinations of medications, such as VEGF inhibitors, programmed death-ligand 1 inhibitors, and PARP inhibitors in ovarian cancer treatment, systematic and diverse clinical trials are necessary to establish optimal treatment algorithms for patients with ovarian cancer. The gene discussed is VEGFA; the disease is ovarian carcinoma.